作者:John J. Acton、Regina M. Black、A. Brian Jones、David E. Moller、Lawrence Colwell、Thomas W. Doebber、Karen L. MacNaul、Joel Berger、Harold B. Wood
DOI:10.1016/j.bmcl.2004.10.068
日期:2005.1
Routine screening for human PPAR ligands yielded compounds 1 and 2, both of which were sub-micromolar hPPARgamma agonists. Synthetic modifications of these leads led to a series of potent substituted 3-benzyl-2-methyl indoles, a subset of which were noted to be selective PPARgamma modulators (SPPARgammaMs). SPPARgammaM 24 displayed robust anti-diabetic activity with an improved therapeutic window in comparison to a PPARgamma full agonist in a rodent efficacy model. (C) 2004 Elsevier Ltd. All rights reserved.